Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company’s recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron’s commitment to corporate responsibility, from how it innovates to how it operates, for the good of its business and humanity TARR